Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation.
Acute lung injury is a frequent and treatment-limiting consequence of therapy with hyperoxic gas mixtures. To determine if IL-11 is protective in oxygen toxicity, we compared the effects of 100% O2 on transgenic mice that overexpress IL-11 in the lung and transgene (-) controls. IL-11 markedly enhanced survival in 100% O2 with 100% of transgene (-) animals dying within 72-96 h and > 90% of transgene (+) animals surviving for more than 10 d. This protection was associated with markedly diminished alveolar-capillary protein leak, endothelial and epithelial membrane injury, lipid peroxidation, and pulmonary neutrophil recruitment. Significant differences in copper zinc superoxide dismutase and catalase activities were not noted and the levels of total, reduced and oxidized glutathione were similar in transgene (+) and (-) animals. Glutathione reductase, glutathione peroxidase, and manganese superoxide dismutase activities were slightly higher in transgene (+) as versus (-) mice after 100% O2 exposure, and IL-11 diminished hyperoxia-induced expression of IL-1 and TNF. Hyperoxia also caused cell death with DNA fragmentation in the lungs of transgene (-) animals and IL-11 markedly diminished this cell death response. These studies demonstrate that IL-11 markedly diminishes hyperoxic lung injury. They also demonstrate this protection is associated with small changes in lung antioxidants, diminished hyperoxia-induced IL-1 and TNF production, and markedly suppressed hyperoxia-induced DNA fragmentation.
Waxman
A B
AB
Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Einarsson
O
O
Seres
T
T
Knickelbein
R G
RG
Warshaw
J B
JB
Johnston
R
R
Homer
R J
RJ
Elias
J A
JA
D000818:Animals; D000975:Antioxidants / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D016923:Cell Death / Q000187:drug effects*; D053938:DNA Fragmentation / Q000187:drug effects*; D004351:Drug Resistance; D018496:Hyperoxia / Q000401:mortality*; D007375:Interleukin-1 / Q000032:analysis; D017370:Interleukin-11 / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D010100:Oxygen / Q000009:adverse effects*; D016019:Survival Analysis; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000975:Antioxidants; D007375:Interleukin-1; D017370:Interleukin-11; D014409:Tumor Necrosis Factor-alpha; D010100:Oxygen